BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hao C, Wang J, Kang W, Xie Y, Zhou Y, Ma L, Peng M, Bai X, Lian J, Jia Z. Kinetics of Th17 Cytokines During Telbivudine Therapy in Patients With Chronic Hepatitis B. Viral Immunology 2013;26:336-42. [DOI: 10.1089/vim.2013.0032] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Feng H, Yin J, Han YP, Zhou XY, Chen S, Yang L, Yan JR, Zhang GX. Sustained Changes of Treg and Th17 Cells During Interferon-α Therapy in Patients with Chronic Hepatitis B. Viral Immunol 2015;28:412-7. [PMID: 26266573 DOI: 10.1089/vim.2015.0024] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
2 Tavakolpour S, Mirsafaei HS, Elkaei Behjati S, Ghasemiadl M, Akhlaghdoust M, Sali S. Toward cure chronic hepatitis B infection and hepatocellular carcinoma prevention: Lessons learned from nucleos(t)ide analogues therapy. Immunol Lett 2017;190:206-12. [PMID: 28827021 DOI: 10.1016/j.imlet.2017.08.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
3 Paquissi FC. Immunity and Fibrogenesis: The Role of Th17/IL-17 Axis in HBV and HCV-induced Chronic Hepatitis and Progression to Cirrhosis. Front Immunol. 2017;8:1195. [PMID: 29033929 DOI: 10.3389/fimmu.2017.01195] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 6.8] [Reference Citation Analysis]
4 Wang ML, Zhou QL, Chen EQ, Du LY, Yan LB, Bai L, He M, Tang H. Low Ratio of Treg to Th17 Cells After 36 Weeks of Telbivudine Therapy Predict HBeAg Seroconversion. Viral Immunol 2016;29:332-42. [PMID: 27104358 DOI: 10.1089/vim.2016.0007] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
5 Harkisoen S, Kroon S, van Erpecum KJ, Hoepelman AI, Baarle DV, Arends JE. The influences of antiviral therapy on T-cell function in adult patients with chronic hepatitis B. Future Virology 2014;9:913-20. [DOI: 10.2217/fvl.14.76] [Reference Citation Analysis]
6 Diao H, He J, Zheng Q, Chen J, Cui G, Wei Y, Ye P, Kohanawa M, Li L. A possible role for NKT-like cells in patients with chronic hepatitis B during telbivudine treatment. Immunol Lett 2014;160:65-71. [PMID: 24718278 DOI: 10.1016/j.imlet.2014.03.013] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
7 Zhang K, Liu Y, Yang X, Sun H, Shu X, Zhang Y, Cao H, Wu M, Liu N, Zou Y, Xu Q, Li G. HBV promotes the recruitment of IL-17 secreting T cells via chemokines CCL22 and CCL17. Liver Int 2020;40:1327-38. [PMID: 32187823 DOI: 10.1111/liv.14438] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
8 Hao C, Zhou Y, He Y, Fan C, Sun L, Wei X, Wang L, Peng M, Wang P, Lian J, Jia Z. Imbalance of regulatory T cells and T helper type 17 cells in patients with chronic hepatitis C. Immunology 2014;143:531-8. [PMID: 24903732 DOI: 10.1111/imm.12330] [Cited by in Crossref: 20] [Cited by in F6Publishing: 24] [Article Influence: 2.9] [Reference Citation Analysis]
9 Liu N, Liu B, Zhang L, Li H, Chen Z, Luo A, Chen M, Peng M, Yin W, Ren H, Hu P. Recovery of circulating CD56dim NK cells and the balance of Th17/Treg after nucleoside analog therapy in patients with chronic hepatitis B and low levels of HBsAg. Int Immunopharmacol 2018;62:59-66. [PMID: 29990695 DOI: 10.1016/j.intimp.2018.06.043] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]